In the fight against triple-negative breast cancer, combination therapy shows promise.

Worldwide, breast cancer is the most common cancer affecting women and occasionally affects men as well.
Triple-negative breast cancer is one of the most difficult to treat of the numerous types of breast cancer.
Two inhibitors have been identified in a new cell study that, when used together, cause triple-negative breast cancer cells to return to a state where they can be destroyed more easily.
The scientists recommend that their discoveries ought to be affirmed in clinical preliminaries to decide if they could shape the premise of another therapy for this hard-to-treat sort of bosom disease.